Clinical Report: Poroid Hidradenoma in the Eyelid: A Case Study
Overview
This report details a case of poroid hidradenoma (PH) in an 88-year-old female, highlighting its atypical presentation on the eyelid. The diagnosis was confirmed through histopathological evaluation following excisional biopsy, with no recurrence noted at the 3-month follow-up.
Background
Poroid hidradenoma is a rare, benign neoplasm originating from eccrine sweat glands, primarily affecting older adults. Its occurrence in the eyelid is uncommon, which poses diagnostic challenges for healthcare professionals. Understanding its clinical presentation and histological characteristics is essential for accurate diagnosis and management.
Data Highlights
No numerical data or trial data available in the article.
Key Findings
Poroid hidradenoma is a benign neoplasm derived from eccrine sweat glands.
The case presented involved an 88-year-old female with a 2-year history of a non-tender eyelid mass.
Histopathological examination revealed well-defined solid and cystic elements with a pseudocapsule.
At 3-month follow-up, there were no signs of recurrence.
Diagnosis relies heavily on histological evaluation due to the challenges in distinguishing PH from other adnexal tumors.
Clinical Implications
Surgical excision remains the standard treatment for poroid hidradenoma, and clear margins are crucial to prevent recurrence. Clinicians should be aware of the potential for PH to occur in atypical locations such as the eyelid, necessitating careful evaluation and histological confirmation.
Conclusion
This case underscores the importance of recognizing poroid hidradenoma in unusual sites and highlights the need for histopathological assessment to ensure accurate diagnosis and appropriate management.
In the management of stage I testicular cancer, a persistent clinical dilemma is the identification of patients who truly need adjuvant treatment after orchiectomy rather than active surveillance alon...
Despite compelling prognostic associations across multiple retrospective data sets, no interventional trial has demonstrated that acting on circulating tumor DNA testing results in early breast cancer...
